Political fears have crushed this sector and it is now very oversold. With Clinton, Warren and Sanders all attacking the biotech stocks on a weekly basis the sector is now very oversold and the election is only ten days away. If Clinton does not win, there could be a monster rebound.
NEW DIRECTIONAL CALL PLAYS
XBI - Biotech ETF ETF Profile
The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index.
The XBI traded up to $69 in late September and has since crashed back to support at $56 as various biotech stocks released data on drug trials that were not successful, were involved in drug pricing schemes or simply issued a profit warning as was the case with Illumina.
The three weeks of headlines over the EpiPen pricing disaster pushed all the drugs stocks lower on worries of drug price controls.
Comments from Clinton, Warren and Sanders about drug pricing concerns also caused investors to flee the biotech sector.
The biotechs may have ended their decline in fear of Hillary Clinton. After the news on Friday about the FBI reopening the criminal investigation on her emails, that should make it really tough to win the election. That means the biotech sector could begin to rebound even before the vote if the polls tighten even further or move into Trump's favor.
On Friday 10/28, the healthcare sector imploded on earnings and warnings from several companies including McKesson, AmerisourceBergen, Cardinal Health and others. The XBI failed to decline after hitting support at $56.
With the XBI now -18% off its September high, all of those factors above are baked into the market. This may be time to place a bet on a biotech rebound.
The ETF has support at $56 and the 200-day at $56.55. The dip on Friday penetrated to $55.80 but then rebounded $1 in a weak market.
I am recommending we buy a cheap December call ahead of the polls that will be out next week. If Clinton does win, we will exit on any weakness.
With a XBI trade at $58
Buy Dec $60 call, currently $2.07, no initial stop loss.
NEW DIRECTIONAL PUT PLAYS
No New Bearish Plays